5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – Pipeline Review, H1 2018’, provides in depth analysis on 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology under development targeting 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)

– The report reviews 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects

– The report assesses 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Bristol-Myers Squibb Co

Corvus Pharmaceuticals Inc

Innate Pharma SA

MedImmune LLC

Surface Oncology Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Overview

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Companies Involved in Therapeutics Development

Bristol-Myers Squibb Co

Corvus Pharmaceuticals Inc

Innate Pharma SA

MedImmune LLC

Surface Oncology Inc

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Drug Profiles

AB-680 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986179 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPX-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab + oleclumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPH-53 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oleclumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-1509 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Dormant Products

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC

3.1.3.5) - Product Development Milestones

Featured News & Press Releases

Dec 19, 2016: Surface Oncology Announces Collaboration with Dr. John Stagg, a World-Leader in the Adenosine Pathway

Apr 18, 2016: Innate Pharma presents new CD73 checkpoint inhibitor program

Feb 24, 2014: CD73 Research Could Lead to Cancer Drug

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Bristol-Myers Squibb Co, H1 2018

Pipeline by Corvus Pharmaceuticals Inc, H1 2018

Pipeline by Innate Pharma SA, H1 2018

Pipeline by MedImmune LLC, H1 2018

Pipeline by Surface Oncology Inc, H1 2018

Dormant Projects, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports